NRx Pharmaceuticals, Inc. today announced its financial results for the third quarter of 2022 and provided a business and clinical update.
Relief Therapeutics Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) (“Relief”), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) (“NRx Pharmaceuticals”), today announced that they have entered into definitive settlement agreements to resolve their pending litigation.
NRx Pharmaceuticals, Inc. today announced that management will report third quarter 2022 financial results prior to the market open on November 14, 2022.
NRx Pharmaceuticals, Inc. today announced the release of the first batches manufactured in the U.S. of NRX-101, its Phase 3-ready investigational drug, targeting suicidal bipolar depression and with future study plans for post-traumatic stress disorder (PTSD).
NRx Pharmaceuticals, Inc. today announced that it has obtained approximately $11 million in unsecured debt financing (the “Note”) from Streeterville Capital, LLC, a Utah limited liability company.
NRx Pharmaceuticals, Inc. today announced its Chief Executive Officer, Stephen Willard, and other executive leaders will be presenting an update to the company’s business at the H.C. Wainwright & Co. 24th Annual Global Investment Conference.
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. today announced that they have agreed to a tentative settlement of their pending litigation. The parties have agreed to work collaboratively to finalize the settlement within the next 30 days.
NRx Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2022 and provided a business and clinical update.
NRx Pharmaceuticals, Inc. today announced that management will report second quarter 2022 financial results prior to the market open on August 15, 2022.
NRx Pharmaceuticals, Inc. today announced the appointment of Stephen Willard, as its Chief Executive Officer and a member of the Company’s Board of Directors.
